Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype
WiN Study Group
(2022) Haemophilia, volume 28, issue 2, pp. 278 - 285
(Article)
Abstract
Introduction: The negative impact of haemophilia on social participation is well established in previous studies, however, the impact of Von Willebrand disease (VWD) on social participation has not been studied. Aim: To compare the social participation of a large cohort of VWD patients in the Netherlands with the general Dutch
... read more
population. In addition, to identify factors associated with social participation in VWD. Methods: Patients participating in the “Willebrand in the Netherlands” study completed an extensive questionnaire on educational level, absenteeism from school or work, and occupational disabilities. Results: Seven-hundred and eighty-eight VWD patients were included (mean age 38.9 years, 59.5% females), of whom 136 children < 16 years. Adult patients with type 3 VWD more often had a low educational level (52.9%) compared to type 1 (40.2%), type 2 VWD (36.8%) and the general population (36.4%) (p =.005). Moreover, in patients aged ≥16 years the days lost from school and/or work in the year prior to study inclusion differed significantly between the VWD types (p =.011). Using negative binomial regression analysis, the occurrence of bleeding episodes requiring treatment in the year preceding study inclusion was significantly associated with the number of days lost from school and/or work among patients aged ≥16 years. Multivariable logistic regression analysis showed that a higher total bleeding score, older age and presence of at least one comorbidity were significantly associated with occupational disability in patients aged ≥16 years. Conclusion: Our study shows that social participation was lower in type 3 VWD and VWD patients with a more severe bleeding phenotype.
show less
Download/Full Text
Keywords: Adolescent, Adult, Female, Hemorrhage/complications, Humans, Male, Phenotype, Social Participation, von Willebrand Disease, Type 1/complications, von Willebrand Disease, Type 3/complications, von Willebrand Diseases/complications, von Willebrand Factor/genetics, von Willebrand Diseases, bleeding, cross-sectional studies, absenteeism, educational status, social participation, Genetics(clinical), Hematology, Journal Article
ISSN: 1351-8216
Publisher: Wiley-Blackwell
Note: Funding Information: has received travel grants from Bayer and Takeda, and consultancy grants from Takeda and Novo Nordisk. received unrestricted research support from CSL Behring and Bayer and speakers fee from Takeda and Amgen. reports speaker fees from Bayer and Alexion, participation in trial steering committee for Bayer, consulting fees from Uniqure, participation in data monitoring and endpoint adjudication committee for all fees go to the institution. has received investigator‐initiated research‐ and travel grants over the years from the Netherlands Organisation for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Dutch “Innovatiefonds Zorgverzekeraars”, Baxter/Baxalta/Shire, Pfizer, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis and Nordic Pharma, and has served as a steering board member for Roche, Bayer and Novartis. All grants, awards and fees go to the Erasmus MC as institution. has been a teacher on educational activities of Bayer and received consultancy fees from Novo Nordisk, paid to the Leiden University Medical Center. The institution of has received unrestricted research grants from CSL Behring, Sobi and NovoNordisk and her institution received consultancy fees from Grifols, Takeda, Novo Nordisk and Roche. received research support from CSL Behring and he has been a teacher on educational activities of Roche. received the CSL Behring‐professor Heimburger Award 2018 and a travel grant from Sobi. received research support from CSL Behring and Shire/Takeda for performing the Willebrand in the Netherlands (WiN) study and Sobi and uniQure for studies not related to this manuscript, and is consultant for uniQure, Sobi, Biomarin and Shire/Takeda, of which the fees go to the institution, and has received a travel grant from Sobi. He is also a DSMB member for a study by Roche. None of the other authors has a conflict of interest to declare. S.E.M. Schols K.P.M. van Galen K. Meijer M.H. Cnossen J.G. van der Bom K. Fijnvandraat J. Eikenboom F. Atiq F.W.G. Leebeek Funding Information: This study was supported by research funding from the Dutch Haemophilia Foundation (Stichting Haemophilia) and CSL Behring (unrestricted grant). Publisher Copyright: © 2021 The Authors. Haemophilia published by John Wiley & Sons Ltd.
(Peer reviewed)